Antaros Medical is proud to have supported Novo Nordisk in the REMODEL trial (NCT04865770), now being presented at ASN Kidney Week in Houston. This multi-national clinical study was designed to deepen understanding of the kidney-specific effects and underlying mechanisms of GLP-1 receptor agonism in individuals living with type 2 diabetes (T2D) and chronic kidney disease (CKD).
As part of the trial, advanced magnetic resonance imaging (MRI) techniques were used to assess key physiological parameters in the kidney, including oxygenation, perfusion, renal blood flow and inflammation. These imaging-based endpoints can provide valuable insights into how GLP-1 receptor agonists may influence kidney function and disease progression.
The REMODEL trial exemplifies the power of imaging in clinical research, and we are honored to have contributed our expertise to this important work. The results are being presented by Novo Nordisk and their investigators during ASN Kidney Week, highlighting the potential of imaging biomarkers to inform and accelerate therapeutic development in kidney disease.
We’re excited to see the results, and proud to contribute imaging expertise to research in this field.
Abstract title: Mechanistic Effects of Semaglutide on Kidney Disease in Type 2 Diabetes: The REMODEL Trial
Abstract number: FR-OR089
Authors: Tuttle K R, Bjornstad P, Pruijm M, Hodgin J B, Cherney D, Belmar N, Chacko M M, Das V, Idorn T, Schytz P A, Kretzler M
Session: Late-Breaking Research Orals – 2 (Friday, November 7 @14.42 pm CT)
About chronic kidney disease and imaging
Chronic kidney disease (CKD) is a global health challenge, yet drug development in this area is slowed by the lack of reliable, non-invasive biomarkers. Traditional markers like eGFR and proteinuria provide limited insight into disease mechanisms, while kidney biopsy is invasive and impractical for clinical trials.
To advance innovation, the field needs biomarkers that can detect kidney damage early, monitor treatment response, and support patient stratification. Imaging techniques, particularly multiparametric MRI, offer a promising solution. MRI enables detailed, reproducible assessment of kidney structure and function, and provide early signals of efficacy and mechanism of action. Imaging biomarkers can support smarter trial design and help accelerate progress in CKD drug development.
Read more about Antaros Medical’s work with kidney imaging here.